Amivantamab has since been granted accelerated approval by the FDA for patients with NSCLC exhibiting EGFR exon 20 insertions who have progressed on platinum-based therapies, where its high-capacity for ADCC induction may be contributing to its favorable efficacy (226). This evidence concerns the gene EGFR and non-small cell lung carcinoma.